GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Net Income Including Noncontrolling Interests

Karolinska Development AB (Karolinska Development AB) Net Income Including Noncontrolling Interests : $3.08 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Karolinska Development AB's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was $0.02 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was $3.08 Mil.


Karolinska Development AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Karolinska Development AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Net Income Including Noncontrolling Interests Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.12 -24.81 18.79 -8.49 0.53

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.67 2.16 1.08 -0.18 0.02

Karolinska Development AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.